Cerus affirms positive results for Phase 3 transfusion study assessing INTERCEPT RBC’s in…
Cerus Corporation asserted successful achievement of primary efficacy and safety endpoints in the Company's Phase 3 transfusion study of Chronic anaemia assessing INTERCEPT-treated Red…
Read More...
Read More...